Landogrozumab

Landogrozumab (INN; development code LY2495655) is a humanized monoclonal antibody and experimental pharmaceutical drug designed for the treatment of muscle wasting disorders.

[1][2] The drug was developed by Eli Lilly and Company.

This monoclonal antibody–related article is a stub.

You can help Wikipedia by expanding it.